Clinical trial
A Multicentre, Double-blind, Parallel, Randomized, Placebo-controlled Study : Evaluation of the Efficacy and Safety of Levocetirizine 5 mg and Desloratadine 5 mg Administered Orally as Capsules Once Daily, in the Morning, Over 2 Weeks in Patients Suffering From Allergic Rhinitis (AR)
NCT00160589 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicentre, Double-blind, Parallel, Randomized, Placebo-controlled Study : Evaluation of the Efficacy and Safety of Levocetirizine 5 mg and Desloratadine 5 mg Administered Orally as Capsules Once Daily, in the Morning, Over 2 Weeks in Patients Suffering From Allergic Rhinitis (AR)
- Lead sponsor
- UCB Pharma
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- April 30, 2005
- Completion date
- September 30, 2005
- Enrollment
- 729
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.